138751-19-6

Basic information

• Product Name: Phosphonic acid, methyl-, monocyclohexyl ester, (R)-
• CAS NO: 138751-19-6
• Molecular Formula: C7H15O3P
• Molecular Weight: 178.168
• Mol File: 138751-19-6.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: Phosphonic acid, methyl-, monocyclohexyl ester, (R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Phosphonic acid, methyl-, monocyclohexyl ester, (R)-(138751-19-6)
• EPA Substance Registry System: Phosphonic acid, methyl-, monocyclohexyl ester, (R)-(138751-19-6)

Safety Data

• Hazardous Substances Data: 138751-19-6(Hazardous Substances Data)

Usage

General Description

Phosphonic acid, methyl-, monocyclohexyl ester, (R)- is a specific chemical compound that belongs to the class of organophosphorus compounds. It is also known by its chemical formula C8H17O3P. This chemical is commonly used as a stabilizer and a dispersing agent in various industrial applications, including water treatment, scale and corrosion inhibition, and metal surface treatment. It is also utilized in the production of agricultural chemicals and pharmaceuticals. Additionally, (R)-Phosphonic acid, methyl-, monocyclohexyl ester is used as an intermediate in the synthesis of other organic compounds. It is important to handle and use this chemical with caution, as it may pose health and environmental risks if not managed properly.

Upstream product

• 329-99-7 GF 

Relevant articles and documents

Reversed enantioselectivity of diisopropyl fluorophosphatase against organophosphorus nerve agents by rational design

Diisopropyl fluorophosphatase (DFPase) from Loligo vulgaris is an efficient and robust biocatalyst for the hydrolysis of a range of highly toxic organophosphorus compounds including the nerve agents sarin, soman, and cyclosarin. In contrast to the substrate diisopropyl fluorophosphate (DFP) the nerve agents possess an asymmetric phosphorus atom, which leads to pairs of enantiomers that display markedly different toxicities. Wild-type DFPase prefers the less toxic stereoisomers of the substrates which leads to slower detoxification despite rapid hydrolysis. Enzyme engineering efforts based on rational design yielded two quadruple enzyme mutants with reversed enantioselectivity and overall enhanced activity against tested nerve agents. The reversed stereochemical preference is explained through modeling studies and the crystal structures of the two mutants. Using the engineered mutants in combination with wild-type DFPase leads to significantly enhanced activity and detoxification, which is especially important for personal decontamination. Our findings may also be of relevance for the structurally related enzyme human paraoxonase (PON), which is of considerable interest as a potential catalytic in vivo scavenger in case of organophosphorus poisoning.